Charles River Laboratories Intl. Inc (NYSE:CRL) VP William D. Barbo sold 6,901 shares of Charles River Laboratories Intl. stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $172.11, for a total transaction of $1,187,731.11. Following the completion of the transaction, the vice president now owns 18,931 shares of the company’s stock, valued at approximately $3,258,214.41. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

CRL stock opened at $176.48 on Friday. The company has a debt-to-equity ratio of 1.20, a current ratio of 1.44 and a quick ratio of 1.20. The company has a 50 day moving average price of $157.46 and a 200 day moving average price of $141.17. Charles River Laboratories Intl. Inc has a fifty-two week low of $123.17 and a fifty-two week high of $176.89. The stock has a market capitalization of $8.44 billion, a PE ratio of 34.88, a price-to-earnings-growth ratio of 1.91 and a beta of 1.18.

Charles River Laboratories Intl. (NYSE:CRL) last posted its quarterly earnings data on Tuesday, February 11th. The medical research company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.83 by $0.18. Charles River Laboratories Intl. had a net margin of 9.61% and a return on equity of 22.17%. The firm had revenue of $691.10 million during the quarter, compared to analysts’ expectations of $685.46 million. During the same quarter in the previous year, the company posted $1.49 EPS. Charles River Laboratories Intl.’s revenue was up 14.1% on a year-over-year basis. As a group, equities analysts expect that Charles River Laboratories Intl. Inc will post 7.54 earnings per share for the current fiscal year.

A number of hedge funds have recently bought and sold shares of the stock. Point72 Hong Kong Ltd acquired a new position in shares of Charles River Laboratories Intl. in the 4th quarter valued at $297,000. Point72 Asset Management L.P. grew its holdings in shares of Charles River Laboratories Intl. by 1,215.7% in the 4th quarter. Point72 Asset Management L.P. now owns 156,872 shares of the medical research company’s stock valued at $23,964,000 after buying an additional 144,949 shares during the period. Sculptor Capital LP grew its holdings in shares of Charles River Laboratories Intl. by 5.1% in the 4th quarter. Sculptor Capital LP now owns 459,586 shares of the medical research company’s stock valued at $70,206,000 after buying an additional 22,500 shares during the period. Captrust Financial Advisors grew its holdings in shares of Charles River Laboratories Intl. by 362.3% in the 4th quarter. Captrust Financial Advisors now owns 2,635 shares of the medical research company’s stock valued at $406,000 after buying an additional 2,065 shares during the period. Finally, Gabelli Funds LLC grew its holdings in shares of Charles River Laboratories Intl. by 8.3% in the 4th quarter. Gabelli Funds LLC now owns 35,861 shares of the medical research company’s stock valued at $5,478,000 after buying an additional 2,750 shares during the period. Hedge funds and other institutional investors own 95.78% of the company’s stock.

A number of research firms have recently issued reports on CRL. Wells Fargo & Co began coverage on shares of Charles River Laboratories Intl. in a research note on Tuesday, January 7th. They issued an “overweight” rating and a $180.00 target price for the company. Cfra lifted their target price on shares of Charles River Laboratories Intl. from $165.00 to $180.00 and gave the company a “strong-buy” rating in a research note on Tuesday. Citigroup lifted their target price on shares of Charles River Laboratories Intl. from $185.00 to $200.00 and gave the company a “buy” rating in a research note on Wednesday. Argus reiterated a “buy” rating and issued a $170.00 target price on shares of Charles River Laboratories Intl. in a research note on Tuesday, November 19th. Finally, Robert W. Baird reiterated an “outperform” rating and issued a $185.00 target price (up previously from $165.00) on shares of Charles River Laboratories Intl. in a research note on Wednesday. Seven research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. Charles River Laboratories Intl. has a consensus rating of “Buy” and an average target price of $169.33.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Further Reading: How is the LIBOR rate calculated?

Insider Buying and Selling by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.